# IZABRIGHT-Bladder01 (NCT07106762)

> Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

No report yet. It can be ordered.

- Drugs tested: izalontamab brengitecan
- Indication: metastatic urothelial cancer with progression after immunotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07106762
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Urothelial Cancer
- Interventions: Iza-bren; Cisplatin; Gemcitabine; Carboplatin
- Enrollment: 470
- Primary outcome: Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
- Primary outcome: Phase 3: Progression-Free Survival (PFS)
- Primary outcome: Phase 3: Overall Survival (OS)

## Indexed commentary on IZABRIGHT-Bladder01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=izabright-bladder01-nct07106762